This book provides clinicians with the information needed to effectively interpret the literature from observational and interventional cardiovascular outcomes studies. The book begins by providing a historical context of cardiovascular epidemiology, followed by chapters addressing key concepts in the study of cardiovascular disease such as the types of cardiovascular outcomes studies, basic and evolving design and statistical considerations, current guidelines for reducing atherosclerotic cardiovascular disease risk, surrogate markers of cardiovascular disease, challenges in developing evidence-based recommendations for non-pharmacological interventions, an overview of the pharmaceutical development process, and a detailed discussion of the clinical evidence supporting several factors and their relationships with atherosclerotic cardiovascular disease (lipids, inflammation, hemostasis, heart rhythm, blood pressure, diabetes, obesity, and chronic kidney disease).

Cardiovascular Outcomes Research is a must-have resource for physicians and other clinicians, residents, fellows, and medical students in cardiology, endocrinology, primary care, and health promotion and disease prevention.

Offers a comprehensive overview of the historical context of cardiovascular epidemiology Provides clinicians with the tools to interpret observational and interventional cardiovascular outcomes studies Discusses the clinical evidence supporting several factors and their relationships with cardiovascular disease

Autorentext

Dr. Kevin C. Maki is an Adjunct Professor and Dean's Eminent Scholar at Indiana University School of Public Health, Bloomington, IN and the Founder, President and Chief Scientist of Midwest Biomedical Research, Addison, IL. He is a translational scientist and clinical trialist, specializing in the design and conduct of clinical studies in human nutrition, metabolism, and chronic disease risk factor management. Over the past 30 years, he has been an investigator, consultant or statistician for more than 350 clinical trials and observational studies. He is the Co-Editor-in-Chief of the Journal of Clinical Lipidology, the Immediate Past President of the National Lipid Association, President of the Accreditation Council for Clinical Lipidology and a Fellow of the National Lipid Association, the Obesity Society and the American College of Nutrition. He earned a PhD in Epidemiology from the University of Illinois at Chicago's School of Public Health, and an MS in Preventive and Rehabilitative Cardiovascular Health from Benedictine University.
Dr. Don P. Wilson, a pediatric endocrinologist by training, has devoted the past 20 plus years of his career to cardiovascular health and risk prevention in children and adolescents. Recognizing that cardiovascular disease is the leading cause of morbidity and mortality in the U.S. and developed countries, Dr. Wilson developed 3 unique pediatric cardiovascular health and risk prevention programs as a member of the academic faculty of Texas A&M University, University of Arizona, and Texas Christian University. Currently he serves as the Endowed Chair of the Pediatric Cardiovascular Health and Risk Prevention Program at Cook Children's Medical Center in Fort Worth Texas. Dr. Wilson is board certified by the American Board of Clinical Lipidology, a Fellow of the National Lipid Association and currently president of the American Board of Clinical Lipidology. He is a member the Board of Directors of the Southwest Lipid Association, the American Board of Clinical Lipidology and the National Lipid Association. He serves as Associate Editor for the Journal of Clinical Lipidology, the Current Atherosclerosis Reports and EndoText. In addition to being Associate Editor, Dr. Wilson is a reviewer for the Journal of Clinical Lipidology, and over 20 other professional journals, including Atherosclerosis, Journal of Pediatrics, Pediatrics, Clinical Pediatrics, Diabetes/Metabolism Research and Reviews, and International Journal of Obesity. He has authored over 130 peer-reviewed publications, including many which focus on cardiovascular risk burden, prevention, and treatment in children with genetic and acquired disorders of lipid metabolism.

Inhalt
Chapter 1. History of Cardiovascular Epidemiology.- Chapter 2. Types of Cardiovascular Outcomes Studies.- Chapter 3. Basic Statistical Considerations for Cardiovascular Outcomes Studies.- Chapter 4. Evolving Concepts in Cardiovascular Outcomes Studies.- Chapter 5. Current Guidelines for Atherosclerotic Cardiovascular Disease Risk Reduction.- Chapter 6. Surrogate Markers of Cardiovascular Disease.- Chapter 7. Challenges in Developing Evidence-based Recommendations for Non-pharmacological Interventions for Atherosclerotic Cardiovascular Disease Risk Reduction.- Chapter 8. Overview of the Pharmaceutical Development Process for Agents to Influence Cardiovascular Health.- Chapter 9. Lipids and Cardiovascular Outcomes.- Chapter 10. Inflammation and Cardiovascular Outcomes.- Chapter 11. Hemostasis and Cardiovascular Outcomes.- Chapter 12. Cardiac Rhythms and Cardiovascular Outcomes.- Chapter 13. Blood Pressure and CardiovascularOutcomes.- Chapter 14. Diabetes, Obesity, Metabolic Syndrome and Cardiovascular Outcomes.- Chapter 15. Chronic Kidney Disease and Cardiovascular Outcomes.